The medical diagnostics industry is making one more push to protect its technology from Section 101 patent eligibility challenges, but seemed to hit a familiar brick wall Thursday at the U.S. Court of Appeals for the Federal Circuit.

Athena Diagnostics, Oxford University and the Max Planck Institute accuse the Mayo Clinic of infringing their 7,267,820 patent on a technique for diagnosing the neuromuscular disease myasthenia gravis. U.S. District Judge Indira Talwani of Massachusetts ruled the patent ineligible on the ground that Athena, a subsidiary of Quest Diagnostics Inc., had patented a law of nature.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]